The purpose of the amendments made by the Bill... is to reduce costs and regulatory burden for industry. Specifically, the amendments benefit sponsors with multiple similar biologicals in the Register... Those sponsors will no longer be required to maintain multiple entries in the Register for each such product and pay an annual charge for each of those entries.The bill introduces a new subsection 4(1AB) to the Charges Act to permit regulations to specify the amounts of annual charges for these groups. This aligns the treatment of biologicals with existing provisions for medicines and kits. The Therapeutic Goods Administration (TGA) operates on a cost-recovery basis, and these charges fund post-market monitoring and compliance. The bill leaves the specific dollar amounts to delegated legislation (regulations) to provide flexibility for the TGA to adjust fees as regulatory costs evolve [Explanatory Memo page 5].
The primary argument for this Bill is centered on regulatory efficiency and the reduction of "red tape" for the Australian biotechnology and healthcare sectors. By moving from a per-product charging model to a grouped model for similar biologicals, the government is removing a financial disincentive for sponsors to register minor variations of beneficial products. This change ensures that the cost-recovery levies imposed by the TGA are more accurately aligned with the actual regulatory effort required for post-market surveillance, rather than being an arbitrary function of the number of entries in the Register [Judgment].
Furthermore, this amendment addresses a matter of legal consistency. Existing provisions already allow for the grouping of medicines and kits for charging purposes; extending this logic to biologicals ensures that different classes of therapeutic goods are treated equitably under the law. This promotes a more predictable and fair regulatory environment for industry stakeholders, as reflected in the positive feedback received during the TGA's targeted consultation process.
A significant concern regarding this Bill is its reliance on delegated legislation for the setting of fees without the inclusion of a statutory cap in the primary Act. While the Explanatory Memorandum suggests that any such limit would be "arbitrary," the absence of a ceiling reduces the level of direct parliamentary oversight and provides the executive branch with broad discretion to increase charges in the future [Judgment]. This creates a degree of long-term financial uncertainty for sponsors of biological products.
Additionally, there is an epistemic question regarding the impact on the TGA's budget. The Bill is projected to result in a $0.2 million reduction in revenue over three years.[1] While this is a modest amount, it remains unclear whether the administrative savings for the TGA will truly compensate for this loss, or if the shortfall might eventually necessitate higher fees for other therapeutic goods or a reduction in the intensity of post-market monitoring activities [Judgment].
As stated in the Financial Impact Statement on page 2 of the Explanatory Memorandum.
2026-07-02
House of Representatives
Before Senate
Unspecified
Health, Disability and Ageing
Healthcare, Industrial Policy